taking up rights, page-3

I think the lack of interest in PYC in the past has partly to do with the fact that for the average layman investor it is difficult to understand the role of peptides in so called "drug discovery".

Most Biotechs are going directly after a particular disease or condition which investors can relate to even if they dont get the science behind it.

I think the fact that we are starting to hear about more easily undertood "Disease Targets" like say for eg. Astroneca chasing a drug to deal with a common infection encountered in hospitals is more "layman-speak" and a more attractive proposition to invest in, even if it is somewhat indirectly.

Roche hasn't helped by being tight lipped about what targets they are after and how much they are prepared to pay to get at 'em.

Maybe that will change if and when the next stage of the Roche deal is announced. Listening to the CEO's words on progress w.r.t. the Roche investigation certainly gives me positive thoughts about the outcome.

Looking forward to the next 3 to 6 months as a shareholder.